Shoulda gone with VitroGro, page-3

First 3 Last

Share
Profile

Follow
thymus

1,625 Posts.

28

16/10/14

09:59

Post #: 14132446
Share

Originally posted by TDA ↑

Smith & Nephew shares fall as HP802-247 living cell spray-on therapy fails to meet primary endpoint 14-10-2014 COMMENTS (0)Antibiotics and Infectious diseasesBiotechnologyHP802-247ResearchSmith & NephewUK 0 0 0 0 Global medical technology business Smith & Nephew (LSE: SN) has found its Phase III study of HP802-247, a living cell spray-on therapy to heal venomous leg ulcers, did not meet its primary endpoint. The therapy, which is designed to work with the body’s own cells, did not give a statistically significant improvement in healing over placebo in the randomized, double-blind, vehicle-controlled study in North America. Smith & Nephew gained rights to the compound with its $782 million acquisition of Healthpoint in 2012. A second Phase III study in the European Union will continue while the program analysis is completed and is expected to report in 2016. Olivier Bohuon, chief executive of Smith & Nephew, said: “A thorough assessment is underway to determine why the preliminary results of the first Phase III study are inconsistent with the strongly positive Phase IIa/IIb results. While this is an unexpected and disappointing development with this one product, we remain excited by the prospects for advanced wound bioactives as unique treatments for unmet patient needs.” Shares in the company fell 1.5% to 976.5 pence upon the reporting of these disappointing results.

Expand

Venomous leg ulcers are the worst kind !

TIS Price at posting: 30.5¢ Sentiment: Hold Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising!

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

There are more pages in this discussion • 11 more messages in this thread...

First 3 Last

Add TIS (ASX) to my watchlist

Shoulda gone with VitroGro, page-3

Top Stories

Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising!

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Featured News